Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181302 | 0.89 | DRD2 (0.55) | PKMDRD2HTR2AHRH1LMNA | |
| SCHEMBL6181230 | 0.84 | PKM (0.52) | PKMALDH1A1DRD2HTR2AHRH1 | |
| SCHEMBL6184467 | 0.84 | PKM (0.52) | PKMALDH1A1DRD2HTR2AHTR7 | |
| SCHEMBL6181546 | 0.84 | PKM (0.50) | PKMALDH1A1HTR2ALMNAPOLB | |
| SCHEMBL14739433 | 0.83 | CNR1 (0.52) | PKMHTR2ALMNAPOLBKMT2A | |
| SCHEMBL6586501 | 0.82 | HTR7 (0.48) | DRD2HTR2AHTR7KMT2AHTR1A | |
| SCHEMBL9527442 | 0.82 | HTR1A (0.60) | DRD2ADRA1DADRA1AADRA1BPOLB | |
| SCHEMBL9531572 | 0.81 | KAT2B (0.58) | DRD2HTR2AHRH1ADRA1DADRA1A | |
| SCHEMBL5926059 | 0.78 | HTR1A (0.50) | ADRA1AHTR1A | |
| SCHEMBL5926097 | 0.76 | HTR7 (0.56) | PKMDRD2HTR2AHRH1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043314-A1 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | EGIS GYOGYSZERGYAR RT. (HU) | 2005-02-24 | — | — | US | disclosed |
| EP-1430034-B1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2005-02-09 | — | — | EP | disclosed |
| EP-1430034-A1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Egis Gyogyszergyar Rt. (HU) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027078-A1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EGIS Gyógyszergyár Rt. (HU) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043314-A1 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | CYP2C19, CYP2D6, CYP3A5 | PKM 375/4885ALDH1A1 326/4885DRD2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.